Mitral Regurgitation Clinical Trial
— PMAOfficial title:
The Papillary Muscle Approximation Provide Stability of Mitral Valve Repair for Ischemic Mitral Regurgitation
Verified date | January 2017 |
Source | The Federal Centre of Cardiovascular Surgery, Russia |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
Recent publications show that an adjunctive subvalvular repair during mitral annuloplasty for secondary mitral regurgitation effective in preventing recurrent regurgitation. One of these procedures is the papillary muscles approximation. However, the safety and the positive impact of this method are still in doubt.
Status | Active, not recruiting |
Enrollment | 100 |
Est. completion date | March 2021 |
Est. primary completion date | January 2021 |
Accepts healthy volunteers | No |
Gender | All |
Age group | N/A and older |
Eligibility |
Inclusion Criteria: - Ischemic cardiomyopathy, - Ischemic mitral regurgitation. Exclusion Criteria: - Degenerative mitral valve disease, - Unstable angina, - Recent myocardial infarction (< 6 months), - Papillary muscles rupture, - Severe right ventricular dysfunction, - Multiple organ failures, - Concomitant left ventricular reconstruction, - Aortic valve procedures. |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
The Federal Centre of Cardiovascular Surgery, Russia |
Ishikawa S, Ueda K, Kawasaki A, Neya K, Suzuki H. Papillary muscle sandwich plasty for ischemic mitral regurgitation: a new simple technique. J Thorac Cardiovasc Surg. 2008 Jun;135(6):1384-6. doi: 10.1016/j.jtcvs.2007.12.034. — View Citation
Kron IL, Hung J, Overbey JR, Bouchard D, Gelijns AC, Moskowitz AJ, Voisine P, O'Gara PT, Argenziano M, Michler RE, Gillinov M, Puskas JD, Gammie JS, Mack MJ, Smith PK, Sai-Sudhakar C, Gardner TJ, Ailawadi G, Zeng X, O'Sullivan K, Parides MK, Swayze R, Tho — View Citation
Manabe S, Shimokawa T, Fukui T, Tabata M, Takanashi S. Impact of papillary muscle approximation on mitral valve configuration in the surgical correction of ischemic mitral regurgitation. Thorac Cardiovasc Surg. 2012 Jun;60(4):269-74. doi: 10.1055/s-0032-1304536. — View Citation
Rama A, Praschker L, Barreda E, Gandjbakhch I. Papillary muscle approximation for functional ischemic mitral regurgitation. Ann Thorac Surg. 2007 Dec;84(6):2130-1. — View Citation
Roshanali F, Vedadian A, Shoar S, Naderan M, Mandegar MH. Efficacy of papillary muscle approximation in preventing functional mitral regurgitation recurrence in high-risk patients with ischaemic cardiomyopathy and mitral regurgitation. Acta Cardiol. 2013 — View Citation
Wakasa S, Kubota S, Shingu Y, Ooka T, Tachibana T, Matsui Y. The extent of papillary muscle approximation affects mortality and durability of mitral valve repair for ischemic mitral regurgitation. J Cardiothorac Surg. 2014 Jun 3;9:98. doi: 10.1186/1749-80 — View Citation
Yamaguchi A, Adachi K, Yuri K, Kimura N, Kimura C, Tamura A, Adachi H. Reduction of mitral valve leaflet tethering by procedures targeting the subvalvular apparatus in addition to mitral annuloplasty. Circ J. 2013;77(6):1461-5. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Age (years) | Description and comparison of groups of patients | 1 year | |
Other | Body mass index (kg/m^2) | Description and comparison of groups of patients. | 1 year | |
Other | Body surface area (m^2) | Description and comparison of groups of patients. | 1 year | |
Other | NYHA (I, II, III or IV) | Description and comparison of groups of patients. | 1 year | |
Other | EuroSCORE | Description and comparison of groups of patients. | 1 year | |
Other | Six minute walk test (m) | Description and comparison of groups of patients. | 1 year | |
Other | Hypertension (absence, stage 1, 2 or 3) | Description and comparison of groups of patients. Impact of the factor on the long-term survival. | 1 year | |
Other | Diabetes mellitus (absence, insulin-dependent or noninsulin-dependent) | Description and comparison of groups of patients. Impact of the factor on the long-term survival. | 1 year | |
Other | Obesity (absence, class 1, 2 or 3) | Description and comparison of groups of patients. Impact of the factor on the long-term survival. | 1 year | |
Other | Multifocal atherosclerosis (presence or absence) | Description and comparison of groups of patients. Impact of the factor on the long-term survival. | 1 year | |
Other | COPD (absence, GOLD 1, 2, 3 or 4) | Description and comparison of groups of patients. Impact of the factor on the long-term survival. | 1 year | |
Primary | Mitral regurgitation severity (1,2 or 3) | Mitral regurgitation severity is the main indicator of the effectiveness of mitral valve plasty. Evaluation of mitral regurgitation was performed in accordance with the recommendations of the American Society of Echocardiography (ASE). Recurrence of mitral regurgitation 2 and more was considered as significant. | 1 year | |
Secondary | End-diastolic volume (ml), end-systolic volume (ml), stroke volume (ml) | Assessment of left ventricular dimensions. | 1 year | |
Secondary | Ejection fraction (%) | Assessment of myocardial contractility. | 1 year | |
Secondary | Systolic interpapillary muscle distance (mm), diastolic interpapillary muscle distance (mm), coaptation depth (mm), coaptation length (mm) | Assessment of the impact of the surgery on the mitral valve configuration. | 1 year | |
Secondary | Tenting area (mm^2) | Assessment of the impact of the surgery on the configuration of the mitral valve. | 1 year |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03278574 -
Flexible Band vs Rigid Ring for Degenerative Mitral Valve Disease
|
N/A | |
Suspended |
NCT04960280 -
A Study to Evaluate a Computerized Stethoscope Called ©Voqx to Diagnose Heart Disease
|
N/A | |
Recruiting |
NCT05021614 -
Valveclip® Transcatheter Mitral Valve Repair Study
|
N/A | |
Not yet recruiting |
NCT06167213 -
ALLIANCE Mitral: Safety and Effectiveness of SAPIEN X4 Transcatheter Heart Valve - Mitral
|
N/A | |
Not yet recruiting |
NCT06465745 -
AltaValve Pivotal Trial
|
N/A | |
Withdrawn |
NCT05040451 -
Carillon Mitral Contour System for Treatment of Exercise Induced Functional Mitral Regurgitation
|
||
Withdrawn |
NCT03714412 -
Feasibility Study of Patients With Severe MR Treated With the Cardiovalve TMVR System
|
N/A | |
Recruiting |
NCT02592889 -
(MitraClip in Non-Responders to Cardiac Resynchronization Therapy)
|
Phase 4 | |
Completed |
NCT02355418 -
The Role of Myocardial Fibrosis in Degenerative Mitral Regurgitation
|
||
Completed |
NCT01841554 -
Cardioband With Transfemoral Delivery System
|
N/A | |
Not yet recruiting |
NCT01431222 -
Abrogation of Mitral Regurgitation Using the MitraClip System in High-Risk Patients Unsuitable for Surgery
|
Phase 4 | |
Not yet recruiting |
NCT03870516 -
Left Chamber Function in Mitral Regurgitation and Predicting Outcome After Replacement and Targeting for Early Surgery
|
N/A | |
Active, not recruiting |
NCT03230747 -
SAPIEN M3 EFS: Early Feasibility Study of the Edwards SAPIEN M3 System for the Treatment of Mitral Regurgitation
|
N/A | |
Enrolling by invitation |
NCT04031274 -
Transcatheter Treatment for Combined Aortic and Mitral Valve Disease. The Aortic+Mitral TRAnsCatheter (AMTRAC) Valve Registry
|
||
Completed |
NCT05850026 -
Mitral Regurgitation in Hypertrophic Obstructive Cardiomyopathy: Fix it in a Simple, Effective and Durable Way!
|
||
Completed |
NCT05836480 -
Immediate Suboptimal Result of Mitral Valve Repair: Late Implications in a Matched Cohort Study
|
||
Completed |
NCT05836532 -
Long Term Results of Surgical and Percutaneous Double Orefices Mitral Repair in Patient With p2 Prolapse Causing Degenerative Mitral Regurgitation
|
||
Recruiting |
NCT03975998 -
Dutch-AMR: Early Mitral Valve Repair Versus Watchful Waiting in Asymptomatic Patients With Severe Mitral Regurgitation
|
||
Completed |
NCT01162083 -
Identifying an Ideal Cardiopulmonary Exercise Test Parameter
|
N/A | |
Suspended |
NCT00787293 -
Study of Safety and Efficacy of the Percutaneous Reduction of Mitral Valve Regurgitation in Heart Failure Patients
|
Phase 2 |